Effect of Glycemic Status on Antimicrobial Response in T2DM Patients With Recurrent UTI, Prospective Comparative Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 99
- 试验地点
- 1
- 主要终点
- treatment success will be defined as simultaneous absence of symptoms and GUE showing <5 pus cells/HPF and MARS-10 score ≥8. Unit of measure: % of participants meeting all criteria.
研究概览
简要总结
This study looked at how blood sugar control affects treatment of repeated urinary tract infections (UTIs) in people with type 2 diabetes. Ninety-nine patients at Al-Zahraa Teaching Hospital in Iraq were included. Some patients had good blood sugar control, while others did not. All were treated with antibiotics, and doctors checked if the infection was cured after 14 days and if it came back within 30 days. The study helps show how diabetes management can affect recovery from UTIs and the chance of infection returning.
详细描述
Recurrent urinary tract infections (rUTIs) are a frequent complication among patients with type 2 diabetes mellitus (T2DM), associated with impaired immune function, glycosuria, and increased risk of antimicrobial resistance. While UTIs are common in both diabetic and non-diabetic patients, recurrence rates and treatment failures are higher in T2DM. Few prospective studies have evaluated the effect of glycemic control on antimicrobial response in this population.
This prospective comparative study enrolled 99 patients with recurrent UTIs, including 58 with T2DM, at Al-Zahraa Teaching Hospital, Wasit Province, Iraq. Patients with diabetes were stratified into groups based on glycemic control (good vs. poor). Antimicrobial therapy was administered according to hospital guidelines, and treatment response was evaluated after 14 days (clinical cure). Patients were followed for 30 days to monitor recurrence.
The primary objective was to assess whether glycemic status influences antimicrobial treatment outcomes in patients with rUTIs. Secondary objectives included evaluating recurrence rates and identifying potential risk factors for treatment failure. Findings from this study highlight the importance of optimizing glycemic control as part of the overall management of recurrent UTIs in patients with T2DM.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients age >18 years, both sex
- •Patient with known history of T2DM at least 1 year
- •Patients diagnosed with rUTI according to the positive GUE as in practice guideline
- •Patients with different glycemic status according to the HbA1c level, and on different treatment for T2DM accordingly.
- •Patients with non-diabetic rUTI as active comparator.
- •Patients who had the ability to communicate to answer study questionnaire.
- •Exclusion criteria:
- •Type 1 diabetic patients on insulin therapy were excluded.
- •T2DM Patients who were using Sodium-glucose co-transporter-2 inhibitors (SGLT-2) (because of their renal -related side effect).
- •Patients who received any antimicrobial treatment within the last 72 hours of their enrollment.
- •Women patients with recurrent vaginitis or urinary incontinence.
- •Men patients with BPH or over flow incontinence ( as a cause for r UTI).
- •Patients with chronic disease other than T2DM that may cause rUTI ( eg. CKD, Spinal cord injury. kidney stone).
- •Pregnancy and lactation
排除标准
- 未提供
研究组 & 干预措施
Non-diabetic patients with recurrent UTI
Non diabetic patients with recurrent UTI receiving treatment
干预措施: ciprofloxacin 500 mg tablet (Drug)
Diabetic patients with recurrent UTI
Diabetic patients with recurrent UTI receiving treatments
干预措施: ciprofloxacin 500 mg tablet (Drug)
结局指标
主要结局
treatment success will be defined as simultaneous absence of symptoms and GUE showing <5 pus cells/HPF and MARS-10 score ≥8. Unit of measure: % of participants meeting all criteria.
时间窗: Up to 14 days after completion of antimicrobial therapy
treatment success will be defined as simultaneous absence of symptoms and GUE showing <5 pus cells/HPF after 30 days of treatment initiation
时间窗: Day 30 after treatment initiation
次要结局
未报告次要终点
研究者
Maher Kadhum
Clinical Researcher
Al-Mustansiriyah University